Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is a clinical-stage immunotherapy company founded in 2015. Specializing in developing T cell engagers, Harpoon harnesses the body’s immune system to combat cancer and other serious diseases. Co-founded by Patrick Bauerle and Luke Evnin, the company leverages groundbreaking T cell recruiting antibodies to develop next-generation therapies. Harpoon's innovative platforms include the Tri-specific T cell Activating Construct (TriTAC®), ProTriTAC™, and TriTAC-XR. The TriTAC® platform aims to direct a patient's own immune cells to target and destroy tumor cells, primarily focusing on solid tumors and hematologic malignancies.
One of Harpoon's leading projects is HPN328, targeting delta-like ligand 3 (DLL3). Currently in a Phase 1/2 clinical trial, HPN328 shows promise in treating small cell lung cancer (SCLC) and other neuroendocrine tumors. Interim results indicate a 35% confirmed response rate in all tumor types studied, with higher efficacy observed in non-SCLC neuroendocrine tumors.
Harpoon's innovative approach extends to their proprietary ProTriTAC™ platform, which remains inactive until reaching the tumor, ensuring higher precision and reduced side effects. Additionally, the TriTAC-XR platform is designed to mitigate cytokine release syndrome, a common challenge in T cell therapies.
Financially, Harpoon has secured robust funding through recent PIPE financings, ensuring a solid runway into 2026. Strategic partnerships with leading oncology research centers and a strong focus on regulatory milestones underscore Harpoon's commitment to advancing cancer treatment. For more information, visit www.harpoontx.com.
- HPN328 received Orphan Drug Designation from the FDA in March 2022.
- The company is actively presenting data at major oncology conferences such as ESMO and ASCO-GU.
- Harpoon plans to meet with regulators in early 2024 to discuss further development plans for HPN328.
Seismic Therapeutic, a machine learning immunology company, has appointed Julie Eastland as an Independent Director to its Board. Ms. Eastland brings over 30 years of experience in finance and strategy within clinical stage biotechnology companies. Her expertise spans the drug development process, from discovery to commercialization, particularly in oncology and immunology.
Ms. Eastland most recently served as CEO and Board Director of Harpoon Therapeutics (HARP), which was acquired by Merck & Co in March 2024. She has held various C-level executive roles in both private and public companies, including ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics. Her experience includes guiding biotechnology companies through significant organizational growth and navigating financial and operational challenges.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
What is Harpoon Therapeutics' primary focus?
What is the TriTAC® platform?
What are the recent clinical trial updates for HPN328?
What does the ProTriTAC™ platform do?
What is the significance of TriTAC-XR?
What financial steps has Harpoon taken recently?
What is HPN328 targeting?
When did HPN328 receive Orphan Drug Designation?
Where can I find more information about Harpoon Therapeutics?
What are Harpoon’s plans for HPN328 in 2024?
